AMEX:AIM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has AIM ImmunoTech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AIM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.4%

AIM

0.7%

US Biotechs

1.8%

US Market


1 Year Return

-58.5%

AIM

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: AIM underperformed the US Biotechs industry which returned 21.4% over the past year.

Return vs Market: AIM underperformed the US Market which returned 3.6% over the past year.


Shareholder returns

AIMIndustryMarket
7 Day-7.4%0.7%1.8%
30 Day22.8%4.9%5.6%
90 Day123.6%10.7%-7.4%
1 Year-58.5%-58.5%23.3%22.1%6.1%3.7%
3 Year-90.0%-90.0%36.3%31.7%28.3%19.8%
5 Year-98.0%-98.0%-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is AIM ImmunoTech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AIM ImmunoTech undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AIM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AIM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AIM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AIM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AIM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AIM is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is AIM ImmunoTech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

20.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AIM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AIM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AIM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AIM's revenue (80.6% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: AIM's revenue (80.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AIM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AIM ImmunoTech performed over the past 5 years?

11.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AIM is currently unprofitable.

Growing Profit Margin: AIM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AIM is unprofitable, but has reduced losses over the past 5 years at a rate of 11.8% per year.

Accelerating Growth: Unable to compare AIM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AIM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.3%).


Return on Equity

High ROE: AIM has a negative Return on Equity (-28.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is AIM ImmunoTech's financial position?


Financial Position Analysis

Short Term Liabilities: AIM's short term assets ($29.7M) exceed its short term liabilities ($703.0K).

Long Term Liabilities: AIM's short term assets ($29.7M) exceed its long term liabilities ($6.6M).


Debt to Equity History and Analysis

Debt Level: AIM's debt to equity ratio (12%) is considered satisfactory.

Reducing Debt: AIM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AIM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AIM has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 10.7% each year.


Next Steps

Dividend

What is AIM ImmunoTech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AIM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AIM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AIM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Thomas Equels (66yo)

4.25yrs

Tenure

US$890,247

Compensation

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.) since February 25, 2016 and serves as its President since A ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD890.25K) is above average for companies of similar size in the US market ($USD603.83K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman4.25yrsUS$890.25k0.55% $380.5k
Ellen Lintal
CFO & Chief Accounting Officer0.67yrUS$187.74k0.081% $55.7k
Peter Rodino
COO, Executive Director of Governmental Relations0.58yrUS$430.10k0.20% $138.2k
Ann Marie Coverly
Director of Administration & Human Resources and Deputy Investor Relations Coordinator7.33yrsno datano data
Carol Smith
Chief Manufacturing Officer & Deputy Chief Scientific Officer27.33yrsUS$171.37kno data
Julie Mierau
Controllerno datano datano data
Ralph Cavalli
Vice President of QC & Manufacturing10.08yrsno datano data

5.8yrs

Average Tenure

66yo

Average Age

Experienced Management: AIM's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Equels
Executive Vice Chairman4.25yrsUS$890.25k0.55% $380.5k
Ronald H. Brus
Member of Scientific Advisory Boardno datano datano data
William Mitchell
Independent Chairman of the Board & Chairman of Scientific Advisory Board4.25yrsUS$220.23k0.25% $170.2k
Christopher Nicodemus
Member of Scientific Advisory Boardno datano datano data
Stewart Appelrouth
Independent Director3.75yrsUS$220.23k0.28% $194.1k
W. Burnette
Member of Scientific Advisory Boardno datano datano data

4.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: AIM's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1382.6%.


Top Shareholders

Company Information

AIM ImmunoTech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AIM ImmunoTech Inc.
  • Ticker: AIM
  • Exchange: AMEX
  • Founded: 1966
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$69.172m
  • Shares outstanding: 29.19m
  • Website: https://www.aimimmuno.com

Number of Employees


Location

  • AIM ImmunoTech Inc.
  • 2117 SW Highway 484
  • Ocala
  • Florida
  • 34473
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AIMAMEX (NYSE MKT LLC)YesCommon SharesUSUSDJul 1996
HXB2DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 1996

Biography

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/24 03:09
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.